JAK2 and anemia (phenotype): First clinical reports suggested a benefit of oral JAK1/2 inhibitors on CLE skin lesions, but the systemic use of these drugs is limited by side effects, e.g., anemia and thrombopenia, which mainly depend on JAK2 blockade.